Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is an uncharacterized natural antisense transcript (NAT) located antisense to the CDH13 gene. NATs are widespread in eukaryotic genomes, usually transcribed from the DNA strand opposite to a coding gene. They can regulate gene expression of their paired sense transcript (in this case, CDH13) through multiple mechanisms, including transcriptional interference, chromatin modification, RNA masking, and RNA duplex formation. The functional consequences of NAT expression can be reduced transcription or altered stability of the sense transcript; in general, NATs buffer gene expression and affect gene regulation at the chromatin and RNA processing level, but detailed biological and clinical roles of this specific transcript are not described. No aliases, interacting drugs, or direct disease links have been reported for ENSG00000261103; it is not recognized as a formal therapeutic target and is not used as a marker or safety concern.
Not applicable; no approved or experimental therapies directly act on ENSG00000261103.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CDH13 (ENSG00000261103).